Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Zack Lynch is the founder and executive director of the Neurotechnology Industry Organization (NIO), a global trade association representing companies involved in neuroscience, brain research institutes and patient advocacy groups. He spearheads annual meetings in Washington D.C. to advance the NIO agenda on Capitol Hill, including galvanizing support for the National Neurotechnology Initiative, a $1B piece of legislation aimed at accelerating translational neuroscience. He is the author of The Neuro Revolution: How Brain Science Is Changing our World, published by St. Martin's Press. Lynch also co-founded NeuroInsights, a market research and investment advisory firm. He was the publisher of the investment newsletter, Neurotech Insights, and co-author of NeuroInsights 500-page annual investment analysis of the global neurotech industry. He also developed the NASDAQ NeuroInsights Neurotech Index, a stock tracking index for neuroscience companies, and was founder and CEO of HealthRally, a neurosoftware company focused on wellness motivation. Lynch serves on the advisory board of the McGovern Institute for Brain Research at MIT. He has bachelor's degrees in evolutionary biology and Environmental Science, and a master's degree in economic geography, all from UCLA.
A Compulsion for Brain Science: Zack Lynch (10/17/13) Roughly a third of the world's population feels the burden of some type of brain, spinal cord or peripheral nerve disease: dementia, depression, compulsion, infection, trauma. Understanding the need for investment, awareness and public policy advocacy in finding solutions for these afflictions, Zack Lynch founded the Neurotechnology Industry Organization in 2006, and serves as its executive director. In this interview with The Life Sciences Report, Lynch makes a bullish case for a growing industry and discusses how he proposes to increase funding for neuroscience from both private and public sources, thereby increasing options for patients and opportunities for investors.
"AMBS has acquired and is making progress on a very interesting diagnostic for Alzheimer's disease." (10/17/13) Amarantus BioScience Holdings Inc. - The Life Sciences Report Interview with Zack Lynch More >